China's National Intellectual Property Administration (CNIPA) has, for the first time, dismissed a patent invalidation request solely because the requester admitted the filing was not about correcting an improper patent grant. The requester posted on social media that they filed the invalidation to get the patentee's WeChat contact. CNIPA said no. This is not a curiosity. It is the operational debut of the good faith provisions in China's 2026 Patent Examination Guidelines, and it directly affects how foreign companies defend their Chinese patents against strategic invalidation attacks.

What Happened

On July 28, 2026, the China National Intellectual Property Administration published a decision that the patent community had been waiting for since January.

The facts are straightforward. A Chongqing-based tech company filed an invalidation request against patent ZL201410409378.7, titled "Wireless Network Adjustment Method and Device," owned by another Chinese tech company. The request went through standard formalities review and CNIPA issued the acceptance notice.

The next day, things got interesting.

The requester's verified corporate Weibo account and the legal representative's WeChat public account both posted images titled "Statement," bearing the company's official seal. The statement cited the case number 4W120605 and said, in plain language, that the invalidation was filed for one reason: to obtain the patentee's IP department contact information. It promised to withdraw immediately once contact was made and never file against the patentee again. On Weibo, the requester went further, describing themselves as a "friendly force doing dirty work" and tagging the patentee's executive with the message: add me on WeChat and I'll withdraw right away.

CNIPA's panel noticed. They used an internet evidence preservation platform to capture and authenticate the social media posts. They cross-referenced the corporate seal and representative identity against the formal filing documents. Everything matched.

The panel issued an examination notice stating the obvious: the filing was not a genuine expression of intent to challenge patent validity. It did not meet the threshold under Article 45 of the Patent Law. The requester, confronted with the evidence, did not dispute the facts. They said it was a "momentary impulse" and asked to withdraw.

CNIPA refused the withdrawal. The case was dismissed.

The Legal Framework: Good Faith Goes Operational

China's Patent Law has included a good faith principle since the fourth amendment. Article 20 states that patent applications and enforcement must follow the principle of good faith, and patent rights must not be abused to harm public interests or the legitimate rights of others.

But Article 20 was aimed at patentees. Article 45 is about challengers. It says any entity or individual who "believes" a patent grant does not comply with the law may request invalidation. The word "believes" does a lot of work here. CNIPA's panel read it as requiring genuine belief, not tactical pretense.

The real teeth came from the revised Patent Examination Guidelines, effective January 1, 2026. Part 4, Chapter 3, Section 3.2 now explicitly states that invalidation requests not based on the requester's true expression of intent will not be accepted. The Guidelines also instruct panels to dismiss requests that were improperly accepted, under Part 4, Chapter 1, Section 7.6.

Two cases have now tested these provisions. The first was the Osimertinib (AZD9291) case, where CNIPA dismissed an invalidation against AstraZeneca's patent because the power of attorney signature was likely forged. That case established that false documents violate good faith. The 4W120605 case goes further: even when the documents are real, if the intent is fake, the request dies.

Three Red Lines CNIPA Just Drew

In the official commentary accompanying the decision, CNIPA identified three categories of bad faith invalidation requests that will be dismissed:

Category 1: False Intent. The 4W120605 scenario. The requester uses the invalidation procedure as a tool for something else: getting contact information, applying pressure in a business negotiation, or harassing a competitor. The filing documents may be technically correct, but the stated grounds are a pretext.

Category 2: False Identity. Submitting forged identity documents, fake signatures, or fabricated legal instruments. The Osimertinib case falls here. If the person named as requester did not actually authorize the filing, the request has no legal foundation.

Category 3: False Agency. Using forged agency authorization documents to conceal the real party behind the invalidation. This targets the practice where competitors use shell requesters or undisclosed principals to avoid revealing their strategic interest.

CNIPA stressed an important procedural point: panels will not proactively interrogate every requester's motives. They will act when evidence exists. In 4W120605, the requester published the evidence themselves. In Osimertinib, the patentee provided forensic document examination. The burden is on the patentee to flag suspicious filings and submit proof.

What This Means for Foreign Companies

If you hold Chinese patents and face an invalidation challenge, you now have a weapon that did not exist six months ago.

The old playbook was brutal. Anyone could file an invalidation. You had to respond, regardless of the requester's identity or motivation. The cost of mounting a defense was the same whether the challenge was serious or frivolous. Foreign patent holders were particularly vulnerable because they had no visibility into whether the requester was a genuine challenger or a proxy for a competitor.

Now you can push back. If the filing documents show irregularities, if the requester's identity or motive is questionable, you can raise the good faith objection. CNIPA will investigate.

But the standard is evidence-based, not speculative. You cannot simply claim bad faith. You need something concrete: inconsistent signatures, suspicious filing patterns, public statements contradicting the filing, or documentary proof of a hidden principal.

The broader context matters too. CNIPA, together with the Ministry of Public Security and the State Administration for Market Regulation, launched a "Rectification and Regulation Year" campaign for 2026 targeting IP agency misconduct. This includes cracking down on fake patent applications, straw man filings, and procedural abuse. The 4W120605 decision is not an isolated act. It is part of a coordinated regulatory push.

What You Should Do Now

First, audit your Chinese patent portfolio for active invalidation proceedings. If a pending challenge involves a requester whose identity or motivation looks questionable, raise the good faith objection now. Cite 4W120605 and the 2026 Guidelines.

Second, build evidence-gathering into your patent defense workflow. When an invalidation is filed, do not just focus on the technical arguments. Investigate the requester. Check corporate registrations, social media, prior filing patterns, and agency relationships. If the requester has filed invalidation requests across unrelated technical fields with no apparent business interest, that is a red flag. If the power of attorney or identity documents show discrepancies, flag them immediately.

Third, understand the limits. This is not a silver bullet. CNIPA's stated position is that panels will apply a presumption of good faith. They will not investigate unless evidence raises doubt. If a competitor files through a properly authorized, documentarily clean third party and the technical arguments are credible, the good faith objection will not help you.

Fourth, watch for the next cases. CNIPA has signaled it will publish additional model cases to refine the standards. The boundaries between legitimate strategic invalidation and abuse will become clearer as more decisions come out.

The 4W120605 decision is a useful tool. It is also a signal that China's patent system is maturing beyond its anything-goes phase. The mechanism that lets anyone challenge a patent is staying. But the mechanism that let anyone challenge a patent for any reason is closing.

This article is for informational purposes only and does not constitute legal advice. Patent invalidation proceedings in China involve complex procedural and substantive issues. Companies should consult qualified PRC patent counsel regarding specific matters.